Virpax Pharmaceuticals products

An adjuvant to barrier-based personal protective equipment (PPE) to help mitigate the risks of poorly fitting equipment and over-used PPE with partially compromised barrier layers; AnQlar may be used as a frontline defense against disease spread in close settings; AnQlar may be used by vaccinated and unvaccinated individuals to prevent viral spread; Clinical and commercial manufacturing supply agreement in place; AnQlar shown to inhibit the ability of the virus to replicate at non-toxic concentrations; May prevent the spread of influenza and SARS-CoV-2 for 24 hours; May prevent brain viral load due to flu and SARS-CoV-2; Demonstrated >18 months stability; Targeted delivery in the nasal mucosa where viral infection starts.

Improved drying, less messy, and better bioavailability; Reliable and reproducible blood levels; Improved patient compliance that could result in enhanced therapeutic outcomes; Sustained pain control over 24 hours with one application.

Ultra-Long-Acting Local Anesthetics: Liposomal Encapsulated Bupivacaine; Sustained Non-Opioid Pain Management in Prolonged Field Care and Hospital Settings.

Endogenous peptides with analgesic potential include endorphins via binding to the mu receptor, dynorphins via the kappa receptor and enkephalins via the delta receptor. Kappa and delta opioid agonists have been shown to provide analgesic benefit while sparing mu agonist toxicity1. Preclinical data supports analgesia from enkephalin without significant opioid tolerance or drug liking. Typically, exogenous enkephalins are rapidly degraded and have difficulty accessing the CNS2. Using a novel encapsulation method known as Molecular Envelope Technology (MET), leucine-enkephalin, or L-ENK can be delivered via an intranasal formulation of “protected” nanoparticles. MET increases dwell time in the nares promoting delivery via the olfactory route across the blood brain barrier and into the central nervous system.

Benefits: NobrXiol may be using significantly less pharmaceutical-grade CBD than current FDA approved oral CBD dosing. NobrXiol may achieve higher efficiency via the nasal route and reduce peripheral side effects like dose dumping due to high-fat meals. Since peripheral exposure via the plasma will be reduced by the nose to brain delivery, we believe there will be negligible liver first-pass metabolism. NobrXiol may not be metabolized in the liver avoiding drug to drug interactions caused by oral pharmaceutical-grade CBD. By avoiding the first pass effect Intranasal NobrXiol may eliminate enzymatic degradation or deactivation. Enzymatic deactivation occurs when an enzyme changes the structure of a neurotransmitter so that the receptor no longer recognizes the neurotransmitter.